

EQA round: T13/24 - Immunophenotypisation (study)

Deadline: 21.10.2024

Setup: groups - R (manufacturer of kit); minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D _{max} = acceptable difference
SD = standard deviation	CVP = consensus of all participants	LL = lower limit
CV = coefficient of variation	U _{AV} = expanded uncertainty of the assigned value (k = 2)	UL = upper limit
N _{tot} = total number of the results		N _{eva} = number of the results assessed
N _{out} = number of the results removed before calculation		N _{suc} = number of successful results
		S _{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]	
							AV	U _{AV}	D _{max}	LL	UL				
(637) B lymphocytes (CD5+CD19+)	[% of B]				23							23	19	83	
Sample A		14,5	11	73	23		CVP	14,5	5,4	100%	0	29	23	21	91
(12) Beckman Coulter		12,5	12	95	15	0							15		
(88) Becton Dickinson		17,1	4,1	24	5	0							5		
Other					3	0							3		
								2x 0, 1x 36							
Sample B		14,7	10	70	23		CVP	14,7	5,2	100%	0	29,4	23	20	87
(12) Beckman Coulter		12,4	10	84	15	0							15		
(88) Becton Dickinson		18,7	7,9	42	5	0							5		
Other					3	0							3		
								2x 0, 1x 36							
(638) Isotype switched memory B lymphocytes (CD19+CD27+IgD-)	[% of B]				13							13	10	77	
Sample A		13,5	1,9	14	13		CVP	13,5	1,3	28%	9,72	17,3	13	12	92
(12) Beckman Coulter		13,4	1,7	12	7	0							7		
Other					6	0							6		
								1x 36, 4x 88, 1x 190							
Sample B		0,771	1,1	140	13		CVP	0,771	0,72	100%	0	1,55	13	10	77
(12) Beckman Coulter		0,355	0,3	86	7	0							7		
Other					6	0							6		
								1x 36, 4x 88, 1x 190							
(639) Naive B lymphocytes (CD19+CD27-IgD+)	[% of B]				13							13	11	85	
Sample A		71	4,4	6,1	13		CVP	71	3	14%	61	81	13	12	92
(12) Beckman Coulter		70,8	4	5,7	7	0							7		
Other					6	0							6		
								1x 36, 4x 88, 1x 190							
Sample B		90,5	6,8	7,5	13		CVP	90,5	4,6	14%	77,8	104	13	11	85
(12) Beckman Coulter		92,8	4	4,3	7	0							7		
Other					6	0							6		
								1x 36, 4x 88, 1x 190							
(640) Activated T lymphocytes (HLA-DR+)	[% of T]				41							41	36	88	
Sample A		8,87	5	56	41		CVP	8,87	1,9	100%	0	17,8	41	37	90
(12) Beckman Coulter		9	4,3	48	25	0							25		
(88) Becton Dickinson		9,2	5,6	61	5	0							5		
(190) Exbio Praha		7,18	7,5	100	6	0							6		
Other					5	0							5		
								2x 0, 1x 36, 2x 999							
Sample B		11,2	7	62	41		CVP	11,2	2,7	100%	0	22,4	41	38	93
(12) Beckman Coulter		10,7	5,8	54	25	0							25		
(88) Becton Dickinson		16,4	6,3	39	5	0							5		
(190) Exbio Praha		8,84	10	120	6	0							6		
Other					5	1							5		
								2x 0, 1x 36, 2x 999							
(641) gamma-delta T lymphocytes (CD3+TcRγδ+)	[% of T]				22							22	16	73	
Sample A		8,4	1,2	14	22		CVP	8,4	0,61	28%	6,04	10,8	22	18	82
(12) Beckman Coulter		8,36	1,6	19	14	0							14		
Other					8	0							8		
								2x 0, 1x 36, 1x 58, 4x 88							
Sample B		2,41	2,2	91	22		CVP	2,41	1,1	100%	0	4,82	22	18	82
(12) Beckman Coulter		2,61	2,8	110	14	0							14		
Other					8	0							8		
								2x 0, 1x 36, 1x 58, 4x 88							
(642) T regulatory lymphocytes (CD3+CD4+CD25+CD127low)	[% of Th]				26							26	23	88	
Sample A		6,17	3,9	63	26		CVP	6,17	1,9	100%	0	12,4	26	25	96
(12) Beckman Coulter		6,85	4,4	65	16	0							16		
(88) Becton Dickinson		5,55	1,9	33	5	0							5		
Other					5	0							5		
								1x 0, 1x 36, 2x 190, 1x 999							
Sample B		5,23	3,4	65	26		CVP	5,23	1,6	100%	0	10,5	26	23	88
(12) Beckman Coulter		5,76	4,2	73	16	0							16		
(88) Becton Dickinson		6,15	1,3	20	5	0							5		

EQA round: T13/24 - Immunophenotypisation (study)

Deadline: 21.10.2024

Setup: groups - R (manufacturer of kit); minimal size of the groups n = 5

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL			
Other					5	0	1x 0, 1x 36, 2x 190, 1x 999					5		